High-dose enzyme replacement therapy attenuates cerebroventriculomegaly in a mouse model of mucopolysaccharidosis type II

[1]  Y. Sohn,et al.  Improvement of CNS Defects Via Continuous Intrathecal Enzyme Replacement by Osmotic Pump in Mucopolysaccharidosis Type II Mice , 2013, American journal of medical genetics. Part A.

[2]  Y. Eto,et al.  Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II. , 2012, Molecular genetics and metabolism.

[3]  Y. Sohn,et al.  Auditory characteristics and therapeutic effects of enzyme replacement in mouse model of the mucopolysaccharidosis (MPS) II , 2012, American journal of medical genetics. Part A.

[4]  M. Poe,et al.  Natural Progression of Neurological Disease in Mucopolysaccharidosis Type II , 2011, Pediatrics.

[5]  S. Kim,et al.  Changes in Glycogen and Glycosaminoglycan Levels in Hepatocytes of Iduronate-2-Sulfatase Knockout Mice before and after Recombinant Iduronate-2-Sulfatase Supplementation , 2011, Yonsei medical journal.

[6]  M. Cosma,et al.  Correction of CNS defects in the MPSII mouse model via systemic enzyme replacement therapy , 2010, Human molecular genetics.

[7]  Zheng Fan,et al.  Correlation of Automated Volumetric Analysis of Brain MR Imaging with Cognitive Impairment in a Natural History Study of Mucopolysaccharidosis II , 2010, American Journal of Neuroradiology.

[8]  S. Kim,et al.  Characterization of a novel mucopolysaccharidosis type II mouse model and recombinant AAV2/8 vector-mediated gene therapy , 2010, Molecules and cells.

[9]  J. Abdenur,et al.  Treatment reduces or stabilizes brain imaging abnormalities in patients with MPS I and II. , 2009, Molecular genetics and metabolism.

[10]  M. Cosma,et al.  IDS crossing of the blood-brain barrier corrects CNS defects in MPSII mice. , 2009, American journal of human genetics.

[11]  C. Eng,et al.  Recognition and Diagnosis of Mucopolysaccharidosis II (Hunter Syndrome) , 2008, Pediatrics.

[12]  D. Jin,et al.  Otologic Manifestations of Hunter Syndrome and Their Relationship with Speech Development , 2008, Audiology and Neurotology.

[13]  G. Zaręba.  Idursulfase in Hunter syndrome treatment. , 2007, Drugs of today.

[14]  J. Muenzer,et al.  The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome) , 2007, Journal of Inherited Metabolic Disease.

[15]  J. DaCosta,et al.  Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II. , 2007, Molecular genetics and metabolism.

[16]  C. Eng,et al.  A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome) , 2006, Genetics in Medicine.

[17]  W. Sly,et al.  Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  H J Gundersen,et al.  The efficiency of systematic sampling in stereology and its prediction * , 1987, Journal of microscopy.